An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-112 in human leukocyte antigen-C*08:02–positive adult patients with unresectable, advanced, and/or metastatic solid tumors that are positive for the KRAS G12D mutation.
Punekar S, Pelster M, Becerra C, Hecht J, Paulson A, Grierson P, Morelli M, Leidner R, Kamgar M, Baranda J, Kazmi S, Shergill A, Robinson A, Patel A, Yan Y, van Heijst J, Demars N, Perez A, Cohen S, Fakih M. An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-112 in human leukocyte antigen-C*08:02–positive adult patients with unresectable, advanced, and/or metastatic solid tumors that are positive for the KRAS G12D mutation. Journal Of Clinical Oncology 2024, 42: tps2677-tps2677. DOI: 10.1200/jco.2024.42.16_suppl.tps2677.Peer-Reviewed Original ResearchT cell receptor-engineered T cellsPancreatic ductal adenocarcinomaKRAS G12D mutationG12D mutationT cellsHLA-C*08:02Open-labelSolid tumorsDriver mutationsTCR-T cell therapyLandscape of cancer treatmentPreliminary anti-tumor activityPotential anti-tumor activityRECIST v1.1 criteriaDose-limiting toxicityTargetable driver mutationsDose-escalation studyCD8 T cellsMetastatic solid tumorsOncogenic driver mutationsAscending dose levelsSolid tumor malignanciesLimited treatment optionsFDA-approved therapiesRecombinant IL-2